News coverage about RadNet (NASDAQ:RDNT) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RadNet earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.0745258535222 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of RadNet (NASDAQ RDNT) remained flat at $7.60 during trading on Wednesday. The company had a trading volume of 65,176 shares. The company has a 50-day moving average of $7.60 and a 200-day moving average of $6.49. The stock has a market cap of $358.84 million, a PE ratio of 49.35 and a beta of 1.01. RadNet has a one year low of $5.25 and a one year high of $7.98.
RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Wednesday, May 10th. The medical research company reported ($0.01) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.01). The firm had revenue of $229 million during the quarter, compared to analysts’ expectations of $223.50 million. RadNet had a negative net margin of 0.38% and a negative return on equity of 9.89%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) EPS. On average, analysts expect that RadNet will post $0.24 EPS for the current year.
Separately, Zacks Investment Research raised shares of RadNet from a “sell” rating to a “hold” rating in a research note on Wednesday, May 17th.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact RadNet (NASDAQ:RDNT) Stock Price” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/19/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-radnet-nasdaqrdnt-stock-price.html.
In other RadNet news, insider Norman R. Hames sold 8,074 shares of the stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $7.60, for a total transaction of $61,362.40. Following the sale, the insider now directly owns 413,157 shares in the company, valued at approximately $3,139,993.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Norman R. Hames sold 5,000 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $7.71, for a total transaction of $38,550.00. Following the sale, the insider now owns 422,131 shares in the company, valued at $3,254,630.01. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 262,838 shares of company stock worth $1,955,532. 9.36% of the stock is owned by company insiders.
About RadNet
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
